Information Needs for Treatment Decision-making of Hematopoietic Cell Transplant Patients 65 Years or Older and Caregivers
- 45 Downloads
Hematopoietic cell transplantation (HCT) is a complex and potentially life-threatening treatment option for patients with hematologic malignant and non-malignant diseases. Advances have made HCT a potentially curative treatment option for patients 65 years of age and older (older patients), and patient education resources should be adapted to meet their needs. To better understand the information needs of older patients and their caregivers for HCT treatment decision-making, the National Marrow Donor Program® (NMDP)/Be The Match® conducted a qualitative comprehensive needs assessment. Focus groups, offered in person or by phone, were conducted with older HCT patients and primary caregivers of older HCT patients at three transplant centers in the USA that were selected based on the number of older adults treated and geographic diversity. The one-hour, semi-structured discussions were recorded and transcribed verbatim. The analysis was performed with the NVivo 10 software for identification of conceptual themes. Five telephone and six in person focus groups of patients (n = 35) and caregivers (n = 10) were conducted. Themes that emerged included the following: (1) the need for tailored resources with age-specific recovery expectations; (2) the need for the right amount of information at the right times; and (3) the benefit of peer support. Effective patient education supports learning and treatment decision-making. As HCT increasingly becomes a treatment option for older patients, tailored educational resources are needed. These focus group results can inform and guide the development of new educational resources for older adults with hematologic diseases considering and planning for HCT.
KeywordsTreatment decision-making Hematopoietic cell transplant Older patients Caregivers
The study investigators thank the focus group participants for their thoughtful and candid reflection on their information needs and treatment decision-making process.
Compliance with Ethical Standards
Conflicts of Interest
The authors declare that they have no conflicts of interest.
CIBMTR® (Center for International Blood and Marrow Transplant Research®) is a research collaboration between the National Marrow Donor Program®/Be The Match® and Medical College of Wisconsin. The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI; a contract HHSH234200637015C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014–06-1-0704 and N00014–08-1-0058 from the Office of Naval Research; and grants from AABB; Allos, Inc.; Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Astellas Pharma US, Inc.; Be the Match Foundation; Biogen IDEC; BioMarin Pharmaceutical, Inc.; Biovitrum AB; BloodCenter of Wisconsin; Blue Cross and Blue Shield Association; Bone Marrow Foundation; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Children’s Leukemia Research Association; ClinImmune Labs; CTI Clinical Trial and Consulting Services; Eisai, Inc.; Genentech, Inc.; Genzyme Corporation; Histogenetics, Inc.; HKS Medical Information Systems; Hospira, Inc.; Kirin Brewery Co., Ltd.; The Leukemia & Lymphoma Society; Merck & Company; The Medical College of Wisconsin; Millennium Pharmaceuticals, Inc.; Miller Pharmacal Group; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Nature Publishing Group; Novartis Oncology; Oncology Nursing Society; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Pall Life Sciences; Pfizer Inc.; Schering Corporation; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; StemCyte, Inc.; StemSoft Software, Inc.; Sysmex America, Inc.; THERAKOS, Inc.; Vidacare Corporation; ViraCor Laboratories; ViroPharma, Inc.; and Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, or any other agency of the U.S. Government.
The Health Services Research program is supported in part by Health Resources and Services Administration Contract No. HHSH234200637018C. The views expressed in this article do not reflect the official policy or position of the Health Resources and Services Administration or the National Marrow Donor Program/Be The Match.
- 1.Al Malki MM, Nathwani N, Yang D et al (2018) Melphalan-based reduced-intensity conditioning is associated with favorable disease control and acceptable toxicities in patients older than 70 with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 24:1828–1835. https://doi.org/10.1016/j.bbmt.2018.04.029 CrossRefPubMedGoogle Scholar
- 2.Atallah E, Horowitz MM, Logan B et al (2015) Outcome of patients 65 years and older with myelodysplastic syndrome (MDS) receiving allogeneic hematopoietic stem cell transplantation compared to patients 55-64 years of age. Blood 126:193–193Google Scholar
- 3.Versluis J, Hazenberg CLE, Passweg JR, van Putten W, Maertens J, Biemond BJ, Theobald M, Graux C, Kuball J, Schouten HC, Pabst T, Löwenberg B, Ossenkoppele G, Vellenga E, Cornelissen JJ, HOVON and SAKK Leukemia Groups (2015) Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. Lancet Haematol 2:e427–e436. https://doi.org/10.1016/S2352-3026(15)00148-9 CrossRefPubMedGoogle Scholar
- 4.Sandhu KS, Brunstein C, DeFor T, Bejanyan N, Arora M, Warlick E, Weisdorf D, Ustun C (2016) Umbilical cord blood transplantation outcomes in acute myelogenous leukemia/myelodysplastic syndrome patients aged ≥70 years. Biol Blood Marrow Transplant 22:390–393. https://doi.org/10.1016/j.bbmt.2015.09.020 CrossRefPubMedGoogle Scholar
- 6.D’Souza A, Fretham C (2017) Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR summary slides. http://www.cibmtr.org. Accessed 6 Nov 2018
- 7.Kutner M, Greenberg E, Jin Y, Paulsen C (2006) The health literacy of America’s adults: results from the 2003 National Assessment of Adult Literacy (NCES 2006–483). U.S. Department of Education. National Center for Education Statistics, Washington DCGoogle Scholar
- 8.Institute of Medicine (US) Committee on Health Literacy (2004) Health literacy: a prescription to end confusion. National Academies Press (US), Washington (DC)Google Scholar
- 9.Merriam SB, Caffarella RS, Baumgartner LM (2006) Learning in adulthood: a comprehensive guide, 3rd edn. Jossey-Bass, San FranciscoGoogle Scholar
- 11.John MA (1988) Geragogy: a theory for teaching the elderly, 1st edn. Routledge, New YorkGoogle Scholar
- 12.Posma ER, van Weert JCM, Jansen J, Bensing JM (2009) Older cancer patients’ information and support needs surrounding treatment: an evaluation through the eyes of patients, relatives and professionals. BMC Nurs 8(1). https://doi.org/10.1186/1472-6955-8-1
- 15.Krueger RA (2008) Focus groups: a practical guide for applied research, 4th edn. Sage Publications, Thousand OaksGoogle Scholar
- 16.National Institutes of Health (NIH). In: National Institutes of Health (NIH). https://www.nih.gov/. Accessed 6 Nov 2018
- 20.Jim HSL, Quinn GP, Gwede CK, Cases MG, Barata A, Cessna J, Christie J, Gonzalez L, Koskan A, Pidala J (2014) Patient education in allogeneic hematopoietic cell transplant: what patients wish they had known about quality of life. Bone Marrow Transplant 49:299–303. https://doi.org/10.1038/bmt.2013.158 CrossRefPubMedGoogle Scholar
- 25.Stewart DW, Shamdasani PN, Rook D (2006) Focus groups: theory and practice, 2nd edn. Sage Publications, Inc, Thousand OaksGoogle Scholar